Manish R. Patel, DO

Manish Patel, DO, discusses future directions for investigating hormonal plus immune therapies for the treatment of patients with salivary gland cancer.

Manish Patel, DO, discusses AEs seen with ADT plus pembrolizumab in patients with advanced-stage, androgen receptor–positive salivary gland cancer.

Manish Patel, DO, discusses response rates seen with ADT in combination with pembrolizumab in advanced, androgen receptor–positive salivary gland cancer.

Manish Patel, DO, discussed the single-arm BTCRC HN17-111 study investigating ADT plus pembrolizumab in advanced, AR-positive salivary gland cancer.

Manish Patel, DO, discussed the unmet needs that led to the investigation of ADT plus pembrolizumab in patients with advanced salivary gland carcinoma.

Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.

Manish Patel, MD, DO, discusses choosing a chemoimmunotherapy regimen for patients with advanced, metastatic non–small cell lung cancer.

Manish Patel, DO, discusses the role of CTLA-4 inhibitors in non–small cell lung cancer.

Manish R. Patel, DO, discusses the safety profile of entrectinib in NTRK fusion–positive solid tumors.

Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.

Manish R. Patel, DO, discusses choosing immunotherapy drugs for patients with non–small cell lung cancer.

Manish R. Patel, DO, discusses current questions and research regarding immunotherapy in non–small cell lung cancer.